Royalty Pharma (NASDAQ:RPRX – Get Free Report) and Biofrontera (NASDAQ:BFRI – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.
Earnings & Valuation
This table compares Royalty Pharma and Biofrontera”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Royalty Pharma | $2.38 billion | 15.44 | $770.95 million | $1.45 | 44.04 |
| Biofrontera | $46.17 million | 0.25 | -$10.54 million | ($0.45) | -1.75 |
Royalty Pharma has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Royalty Pharma and Biofrontera, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Royalty Pharma | 0 | 0 | 8 | 0 | 3.00 |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
Royalty Pharma currently has a consensus target price of $61.57, indicating a potential downside of 3.58%. Given Royalty Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Royalty Pharma is more favorable than Biofrontera.
Institutional & Insider Ownership
54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Royalty Pharma and Biofrontera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Royalty Pharma | 32.14% | 30.01% | 14.91% |
| Biofrontera | -13.78% | -145.81% | -31.30% |
Volatility & Risk
Royalty Pharma has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Summary
Royalty Pharma beats Biofrontera on 13 of the 14 factors compared between the two stocks.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
